Indivior Pharmaceuticals Financial Statements
NASDAQ: INDVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 35.83 0.00%
Indivior Pharmaceuticals revenue and earnings
In fiscal 2025, Indivior Pharmaceuticals generated $1.24 billion in revenue, up 4.3% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $210.0 million (+2900.0% year over year), for a net margin of 16.9% versus a median of -2.0% in the prior 4 years. Gross margin was 80.2% (down from 80.6%) and operating margin 21.1%.
Diluted earnings per share came in at $1.64, up from $0.05. Over the last 4 fiscal years, INDV's revenue has grown at a 11.9% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Indivior Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 |
|---|---|---|---|---|---|
| Revenue | 1.24B | 1.19B | 1.09B | 901.00M | 791.00M |
| Revenue growth (YoY) | +4.29% | +8.69% | +21.31% | +13.91% | — |
| Cost of Revenue | 246.00M | 231.00M | 174.00M | 151.00M | 127.00M |
| Gross Profit | 994.00M | 957.00M | 919.00M | 749.00M | 664.00M |
| Operating Expenses | 732.00M | 919.00M | 1.07B | 827.00M | 451.00M |
| Research & Development | 97.00M | 107.00M | 116.00M | 74.00M | 52.00M |
| Selling, General & Admin | 634.00M | 612.00M | 565.00M | 466.00M | 431.00M |
| Operating Income | 262.00M | 38.00M | -152.00M | -77.00M | 213.00M |
| Interest Expense | 45.00M | 41.00M | 35.00M | 27.00M | 27.00M |
| Pretax Income | 239.00M | 20.00M | -145.00M | -86.00M | 190.00M |
| Income Tax | 29.00M | 13.00M | -19.00M | -43.00M | -15.00M |
| Net Income | 210.00M | 7.00M | -126.00M | -42.00M | 205.00M |
| Net Income growth (YoY) | +2900.00% | — | — | -120.49% | — |
| EPS (Basic) | 1.68 | 0.05 | -0.92 | -0.30 | — |
| EPS (Diluted) | 1.64 | 0.05 | -0.92 | -0.30 | — |
| Shares Outstanding (Basic) | 125.00M | 132.00M | 137.00M | 139.00M | 145.66M |
| Shares Outstanding (Diluted) | 128.00M | 133.00M | 137.00M | 139.00M | 151.94M |
| EBITDA | 272.00M | 54.00M | -137.00M | -61.00M | 228.00M |
| Gross Margin | 80.23% | 80.56% | 84.08% | 83.13% | 83.94% |
| Operating Margin | 21.15% | 3.20% | -13.91% | -8.55% | 26.93% |
| Net Margin | 16.95% | 59.00% | -11.53% | -4.66% | 25.92% |
This table shows 5 annual periods of Indivior Pharmaceuticals's income statement, from FY 2025 back to FY 2021, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow INDV's reporting calendar. What is a income statement?